Articles by MD Magazine Staff

Latest Articles

Fidaxomicin in the Treatment of Clostridium Difficile Infections
  |  MD Magazine Staff
Erik Dubberke, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, compare the use of fidaxomicin against standard therapy options, such as vancomycin, for the treatment of Clostridium difficile, suggesting that fidaxomicin may reduce a patient’s risk of recurrence.
Factors That Impact Clostridium Difficile Infection Recurrence
  |  MD Magazine Staff
Following a discussion on how to monitor patients with Clostridium difficile for a response to treatment, Lawrence J. Brandt, MD; Erik Dubberke, MD; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, remark on the risk of recurrence and management of patients’ post therapy and how to proceed if recurrence occurs.
Monitoring for Treatment Response in Clostridium Difficile
  |  MD Magazine Staff
Lawrence J. Brandt, MD; Erik Dubberke, MD; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, highlight markers that may suggest a treatment response in patients who are receiving therapy for Clostridium difficile and discuss how providers are making decisions to manage these patients.
Metronidazole vs Vancomycin in Mild Clostridium Difficile
  |  MD Magazine Staff
Lawrence J. Brandt, MD; Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, discuss provider considerations when making decisions on how to treat patients with Clostridium difficile with the guideline-suggested agents, vancomycin and metronidazole.
When to Suspect Diarrhea is Symptom of a Clostridium Difficile
  |  MD Magazine Staff
Lawrence J. Brandt, MD; Erik Dubberke, MD; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, distinguish between small bowel and large bowel diarrhea in patients with Clostridium difficile and discuss common approaches for diagnosing and managing patients.
Community Sources of Clostridium Difficile
  |  MD Magazine Staff
Following a general discussion on risk factors for Clostridium difficile, Lawrence J. Brandt, MD; Erik Dubberke, MD; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, distinguish which factors increase the likelihood for community onset.
Letermovir Phase III Trial
  |  MD Magazine Staff
Panelists Harry Erba, MD, PhD; Roy Chemaly, MD, MPH; and Mark Levis, MD, PhD, outline the status of the letermovir phase III trial and provide practical advice for improving transplant.
Risk Factors for Developing Clostridium Difficile Infections
  |  MD Magazine Staff
Lawrence J. Brandt, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, cite treatment options and patient-related factors that may increase a person’s risk for developing Clostridium difficile.
Letermovir for CMV Prophylaxis in Transplant Patients
  |  MD Magazine Staff
Panelists Harry Erba, MD, PhD; Mark Levis, MD, PhD; and Roy Chemaly, MD, MPH, provide insight on the practical implications of letermovir in the setting of stem cell transplantation.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$